Radiology Publishes 194-Patient Nexsphere-F Study Showing 57% Knee Pain Reduction
Updated
Updated · BioSpace · Jul 6
Radiology Publishes 194-Patient Nexsphere-F Study Showing 57% Knee Pain Reduction
3 articles · Updated · BioSpace · Jul 6
Summary
194 patients with knee osteoarthritis saw median pain scores fall from 7 to 3 at 12 months after genicular artery embolization with Nexsphere-F, according to a newly published Radiology study.
Across 239 procedures, the fast-resorbable microsphere delivered a 100% technical success rate, with roughly 80% of patients achieving clinically meaningful improvement in knee function and quality of life.
No moderate or severe procedure-related adverse events were reported, and transient skin discoloration occurred in 6.3% of procedures, versus rates cited as high as 65% for permanent microspheres and 18% for IPM-CS in prior studies.
NEXTBIOMEDICAL said the peer-reviewed data should support European expansion under its existing CE mark and strengthen future reimbursement efforts, while its U.S. RESORB trial for FDA approval continues.
This new technique treats knee pain, but could it become a universal cure for arthritis in all joints?
Is this new knee pain fix a permanent solution or just a temporary reprieve from major surgery?
Genicular Artery Embolization for Knee Osteoarthritis: 2026 Evidence, Patient Selection, and Real-World Outcomes
Overview
Genicular Artery Embolization (GAE) is quickly becoming a leading minimally invasive treatment for knee osteoarthritis, offering hope to millions affected by chronic joint pain. As of 2026, GAE is gaining attention from major medical institutions and is being explored for other joint conditions like frozen shoulder and tennis elbow, showing its versatility. The procedure is typically completed in one to two hours under conscious sedation, ensuring patient comfort. With promising results in pain relief and a strong safety profile, GAE stands out as an innovative option for those seeking alternatives to traditional surgery.